MM&M’s Top 100 North American healthcare agencies of 2022
We are happy to announce that PRECISIONvalue has made the list of MM&M’s Top 100 North American healthcare agencies of 2022!
Employers and Benefits Consultants Assess Gene Therapy Costs and Solutions
Our employer expert Jorge Font addresses concerns about the increasing numbers of “seven-figure costs” associated with emerging gene therapy and some of the considerations undertaken to address these rising costs.
Court Decision on Accumulator Rule Could Encourage State Bans
A federal court recently struck down a CMS final rule slated to take effect in 2023 which would have required pharmaceutical manufacturers to ensure that financial assistance provided to patients goes only to patients and not to payers under their copay accumulator and maximizer programs. Despite the ruling, Precision's Ryan Cox and Reta Mourad discuss how the renewed attention to these programs could spur more states to take action of their own against them.
Diabetes Cure or Diabetes Management?
Diabetes deaths in the United States continue to surge well above pre-pandemic levels with over 100,000 Americans dying from diabetes in 2021. Increasing deaths from diabetes is a clear call to action for new solutions. Historically, diabetes has been treated as a chronic disease, managed with a lifetime of medications. However, a new line of thinking about diabetes remission permeates the literature.
Miss any of our Recent Precision Value & Health Events? Check out our June Events Calendar
Miss any of our recent Precision Value & Health events? Check out our monthly marketing activities calendar to catch up on-demand, and stay ahead of upcoming dates!
